SiBone (NASDAQ:SIBN) CEO Sells $220,017.47 in Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 14,957 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $14.71, for a total value of $220,017.47. Following the transaction, the chief executive officer directly owned 503,444 shares of the company’s stock, valued at $7,405,661.24. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Price Performance

Shares of SiBone stock traded down $0.02 during trading on Wednesday, reaching $14.82. 506,954 shares of the company’s stock were exchanged, compared to its average volume of 666,784. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The company has a market cap of $657.25 million, a P/E ratio of -38.00 and a beta of 0.67. The firm’s 50-day moving average price is $13.35 and its 200 day moving average price is $16.10.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The company had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. As a group, research analysts anticipate that SiBone will post -0.44 earnings per share for the current year.

Analysts Set New Price Targets

SIBN has been the subject of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and issued a $18.00 target price (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. TD Cowen lowered their target price on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Hedge Funds Weigh In On SiBone

A number of institutional investors and hedge funds have recently bought and sold shares of SIBN. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the 4th quarter worth about $29,000. Royal Bank of Canada increased its holdings in SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after purchasing an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after purchasing an additional 1,941 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in SiBone in the 3rd quarter worth about $39,000. Finally, Kemnay Advisory Services Inc. acquired a new position in SiBone in the 4th quarter worth about $53,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.